CPTH2

CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) [1][2].

Product Specifications

CAS Number

[357649-93-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Histone Acetyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cpth2.html

Purity

99.82

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 1 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1

Molecular Formula

C14H14ClN3S

Molecular Weight

291.80

Precautions

H302, H315, H319, H335

References & Citations

[1]Cocco E, et al. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumoraggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018 Apr 4;10:44.|[2]Chimenti F, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: cyclopentylidene-[4- (4'-chlorophenyl) thiazol-2-yl) hydrazone. J Med Chem. 2009 Jan 22;52 (2) :530-6.